Lakshmi Kotra - FSD Pharma Chief Inc
| HUGEDelisted Stock | USD 0.09 0 4.56% |
Insider
Lakshmi Kotra is Chief Inc of FSD Pharma Class
| Age | 51 |
| Phone | 416 854 8884 |
| Web | https://www.fsdpharma.com |
FSD Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3374) % which means that it has lost $0.3374 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6403) %, meaning that it created substantial loss on money invested by shareholders. FSD Pharma's management efficiency ratios could be used to measure how well FSD Pharma manages its routine affairs as well as how well it operates its assets and liabilities.FSD Pharma Class currently holds 337.46 K in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. FSD Pharma Class has a current ratio of 3.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about FSD Pharma's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Avi Krivorot | Cannara Biotech | N/A | |
| Zohar Krivorot | Cannara Biotech | 46 | |
| Erica CPA | Biofrontera | 39 | |
| Etienne Ledoux | Cannara Biotech | N/A | |
| Anthony Manouk | Cannara Biotech | N/A | |
| Matthias Heinzel | MERCK Kommanditgesellschaft auf | 56 | |
| Dirk Toepfer | MERCK Kommanditgesellschaft auf | N/A | |
| Belen MD | MERCK Kommanditgesellschaft auf | 63 | |
| Xiaodong Pan | China SXT Pharmaceuticals | 46 | |
| Gerhard Schmitz | MERCK Kommanditgesellschaft auf | 60 | |
| Brian Sherman | Cannara Biotech | N/A | |
| Mark Baldyga | Biofrontera | N/A | |
| David Abitbol | Cannara Biotech | N/A | |
| Barbara Weiland | MERCK Kommanditgesellschaft auf | 49 | |
| Feng Zhou | China SXT Pharmaceuticals | 32 | |
| Friederike Rotsch | MERCK Kommanditgesellschaft auf | 51 | |
| Julia Bouvet | Cannara Biotech | N/A | |
| Eugene III | Biofrontera | 39 | |
| Hermann Lubbert | Biofrontera | 68 | |
| France Landry | Cannara Biotech | N/A | |
| Alexander Wolfe | Cannara Biotech | N/A | |
Management Performance
| Return On Equity | -0.64 | |||
| Return On Asset | -0.34 |
FSD Pharma Class Leadership Team
Elected by the shareholders, the FSD Pharma's board of directors comprises two types of representatives: FSD Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FSD. The board's role is to monitor FSD Pharma's management team and ensure that shareholders' interests are well served. FSD Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FSD Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lakshmi Kotra, Chief Inc | ||
| Kevin Cassidy, Vice QualityLucid | ||
| Donal CPA, Chief Officer | ||
| Zeeshan Saeed, President Director | ||
| Dr BPHARM, CEO Director | ||
| Maryann Adesso, Corporate Secretary | ||
| Nathan CPA, Chief Officer | ||
| Andrzej MD, Vice Lucid | ||
| Anthony Durkacz, Co-Chairman of the Board | ||
| Randell Mack, President BioSciences |
FSD Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FSD Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | 4.57 M | |||
| Shares Outstanding | 46.06 M | |||
| Shares Owned By Insiders | 9.74 % | |||
| Shares Owned By Institutions | 2.81 % | |||
| Number Of Shares Shorted | 176.97 K | |||
| Price To Earning | (1.53) X | |||
| Price To Book | 0.50 X | |||
| Price To Sales | 91.86 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in FSD Stock
If you are still planning to invest in FSD Pharma Class check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FSD Pharma's history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |